Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 13;25(1):103605. doi: 10.1016/j.isci.2021.103605

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Author(s)

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

IL-32 expression in primary myeloma cells is associated with inferior survival, cell division, and oxidative phosphorylation

(A) Overall survival of IL-32 expressing patients (10th percentile) compared with nonexpressing patients (90th percentile) in the IA13 CoMMpass dataset P = 8.9e-5, using Cox proportional-hazards regression model.

(B) IL-32 expression in individual patients at diagnosis and first relapse in RNA-sequenced CD138⁺ cells from CoMMpass IA13. Significance was determined by Wilcoxon signed-rank test.

(C) GO-analysis of the upregulated genes (Benjamini-Hochberg-adjusted p value <0.05; log2 fold change >0 for up-regulated genes) in IL-32-expressing patients (10th percentile) compared with IL-32 nonexpressing patients (90th percentile). Top significantly enriched biological processes upregulated in IL-32 expressing patients are shown. The GO terms are ordered by the Benjamini-hochberg adjusted p values. See also Tables S3 and S4.

(D) Correlation between IL32 and a proliferative index gene signature (calculated as the sum of expression values of the gene set as described in Hose et al. (2009).

(E) GO-analysis of the downregulated genes (Benjamini-Hochberg-adjusted p value <0.05; log2 fold change <0 for down-regulated genes, respectively) in IL-32-expressing patients (10th percentile) compared with IL-32 nonexpressing patients (90th percentile). Top significantly enriched biological processes downregulated in IL-32 expressing patients are shown. The GO terms are ordered by the Benjamini-Hochberg adjusted p values. See also Tables S3 and S4.